General Information of Drug (ID: DM1IZ5D)

Drug Name
Talabostat
Synonyms Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro
Indication
Disease Entry ICD 11 Status REF
Constitutional neutropenia 4B00.0 Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 214.07
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 3
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 4
Chemical Identifiers
Formula
C9H19BN2O3
IUPAC Name
[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid
Canonical SMILES
B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O
InChI
InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1
InChIKey
FKCMADOPPWWGNZ-YUMQZZPRSA-N
Cross-matching ID
PubChem CID
6918572
CAS Number
149682-77-9
DrugBank ID
DB06182
TTD ID
D0FQ2U
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 8 (DPP-8) TTJGLZF DPP8_HUMAN Inhibitor [2]
Dipeptidyl peptidase 9 (DPP-9) TTNDUL7 DPP9_HUMAN Inhibitor [2]
Prolyl endopeptidase FAP (FAP) TTGPQ0F SEPR_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Constitutional neutropenia
ICD Disease Classification 4B00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prolyl endopeptidase FAP (FAP) DTT FAP 2.01E-01 0.07 0.84
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)